INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Tyra Biosciences, Inc.

Pomerantz LLP is investigating potential securities-fraud and other unlawful-business-practice claims involving Tyra Biosciences after the company disclosed Phase 2 SURF302 data for dabogratinib. Although Tyra described the safety profile as favorable, Grade 3 treatment-emergent adverse events occurred in 14% of the 60 mg once-daily cohort and 9% of the 50 mg cohort. TYRA shares fell $4.72, or 17.66%, to $22.01 on September 9, 2026, following the disclosure.

Analysis

The legal notice itself is not a fundamental catalyst; it is an opportunistic response to a disclosed clinical-data drawdown and should not be extrapolated into incremental liability without evidence of a disclosure mismatch. The investable issue is whether the adverse-event profile narrows dabogratinib's usable dose range enough to reduce durable response, treatment duration, or registrational-path confidence. In a small oncology platform, that can drive a disproportionate valuation reset because the lead asset likely accounts for most enterprise value and funding capacity.

Over the next 1-3 months, TYRA is vulnerable to follow-on selling if management cannot clarify discontinuation rates, dose reductions, exposure-adjusted Grade 3 events, and efficacy by dose cohort. Safety concerns are especially material in a low-grade, non-muscle-invasive setting, where tolerability thresholds are higher than in late-line metastatic oncology and competing local or systemic options can limit physician willingness to accept meaningful toxicity. A lower selected dose may preserve development optionality but could lower perceived probability of success until dose-response data are independently de-risked.

The contrarian case is that Grade 3 treatment-emergent events alone are not sufficient to establish an unfavorable benefit-risk profile; attribution, reversibility, discontinuation rates, and efficacy durability matter more than headline incidence. If the company demonstrates that events were manageable and the selected regimen retains clinically differentiated activity, the post-data decline may prove excessive. That is a data-validation setup, not a reason to underwrite litigation headlines as a standalone short catalyst.

For 6-18 months, the critical second-order risk is financing: a sustained lower equity price raises dilution risk ahead of later-stage development and weakens TYRA's negotiating leverage for partnerships. The thesis is falsified positively by clean updated safety/discontinuation disclosure plus compelling dose-level efficacy; it is falsified negatively by a selected-dose downgrade, protocol amendment, delayed regulatory interaction, or cash runway that implies a discounted raise.

Key Decisions for Investors

• Do not trade the Pomerantz notice in isolation; maintain TYRA as a watch-list event rather than initiating a litigation-driven short. Confirm the next update includes discontinuations, dose interruptions, attribution and durability before assigning incremental downside.
• For a bearish biotech sleeve, consider a small 1-3 month TYRA short only after any relief rally that is unsupported by expanded safety detail; target a risk-defined 15-25% downside from entry, with a hard cover if management reports low discontinuation rates and maintains the intended dose/regulatory timeline.
• Prefer defined-risk downside via TYRA put spreads around the next clinical or corporate-update window if liquid options are available. Avoid naked puts after the initial gap: binary clinical updates and short-interest dynamics can produce sharp reversals.
• Monitor cash runway and any ATM/equity-registration activity over the next two quarters. A financing need before a credible safety clarification would strengthen the short thesis through dilution; adequate runway or a non-dilutive partnership would remove a major structural bear case.
• Avoid broad oncology-biotech sector hedges based on this event. The read-through is asset- and indication-specific; use XBI only as beta management, not as an expression of the TYRA safety thesis.